Status:
COMPLETED
Re-Treatment Study of Probuphine in Opioid Addiction
Lead Sponsor:
Titan Pharmaceuticals
Conditions:
Opioid Dependency
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Probuphine (buprenorphine implant) is an investigational implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This is a 6-month, open-...
Eligibility Criteria
Inclusion
- Subject has voluntarily provided written informed consent prior to conducting any study-related procedures
- Completion of 24 weeks of treatment in PRO-806
- Subject has been deemed appropriate for entry into this extension study by the investigator
- Females of childbearing potential must be willing to use a reliable means of contraception during the entire study.
Exclusion
- An aspartate aminotransferase (AST) levels ≥ 3 X the upper limit of normal, alanine aminotransferase (ALT) levels ≥ 3 X the upper limit of normal, total bilirubin ≥ 1.5 X the upper limit of normal, or creatinine ≥ 1.5 X upper limit of normal on the screening laboratory assessments
- A current diagnosis of chronic pain requiring opioids for treatment
- A pregnant or lactating female
- Current use of agents metabolized through Cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), or protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)
- A history of coagulopathy within the past 90 days, and/or current anti-coagulant therapy such as warfarin
- A significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigator would preclude compliance with the protocol, subject safety, adequate cooperation in the study, or obtaining informed consent
- Any current medical conditions such as severe respiratory insufficiency that may prevent the subject from safely participating in study, or any pending legal action that could prohibit participation or compliance in the study
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT01262261
Start Date
November 1 2010
End Date
November 1 2011
Last Update
December 31 2018
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
David Geffen School of Medicine at UCLA
Los Angeles, California, United States, 90025
2
Synergy Clinical Research Center
National City, California, United States, 91950
3
North County Clinical Research
Oceanside, California, United States, 92056
4
Friends Research Institute
Torrance, California, United States, 90502